Balyasny Asset Management L.P. Sells 1,215,578 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Balyasny Asset Management L.P. reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 58.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 849,405 shares of the biopharmaceutical company's stock after selling 1,215,578 shares during the period. Balyasny Asset Management L.P. owned 0.28% of Amicus Therapeutics worth $8,001,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of FOLD. Bayesian Capital Management LP grew its stake in shares of Amicus Therapeutics by 422.7% in the fourth quarter. Bayesian Capital Management LP now owns 66,900 shares of the biopharmaceutical company's stock valued at $630,000 after acquiring an additional 54,100 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Amicus Therapeutics by 4.2% in the fourth quarter. Ameriprise Financial Inc. now owns 403,127 shares of the biopharmaceutical company's stock valued at $3,797,000 after acquiring an additional 16,179 shares in the last quarter. Algert Global LLC grew its stake in shares of Amicus Therapeutics by 64.0% in the fourth quarter. Algert Global LLC now owns 425,083 shares of the biopharmaceutical company's stock valued at $4,004,000 after acquiring an additional 165,923 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Amicus Therapeutics by 7.8% in the fourth quarter. Jane Street Group LLC now owns 324,270 shares of the biopharmaceutical company's stock valued at $3,055,000 after acquiring an additional 23,524 shares in the last quarter. Finally, PDT Partners LLC grew its stake in shares of Amicus Therapeutics by 39.3% in the fourth quarter. PDT Partners LLC now owns 352,498 shares of the biopharmaceutical company's stock valued at $3,321,000 after acquiring an additional 99,539 shares in the last quarter.

Amicus Therapeutics Trading Down 3.1%

NASDAQ:FOLD traded down $0.19 on Tuesday, reaching $6.02. 3,770,706 shares of the stock traded hands, compared to its average volume of 2,779,935. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 1-year low of $5.82 and a 1-year high of $12.65. The company's 50 day moving average is $7.59 and its 200-day moving average is $9.04. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -33.44, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on FOLD shares. UBS Group increased their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, The Goldman Sachs Group dropped their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.